Michael P. Douglas

3.0k total citations · 1 hit paper
61 papers, 2.0k citations indexed

About

Michael P. Douglas is a scholar working on Genetics, Cancer Research and Economics and Econometrics. According to data from OpenAlex, Michael P. Douglas has authored 61 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Genetics, 19 papers in Cancer Research and 14 papers in Economics and Econometrics. Recurrent topics in Michael P. Douglas's work include Genomics and Rare Diseases (23 papers), Cancer Genomics and Diagnostics (18 papers) and BRCA gene mutations in cancer (14 papers). Michael P. Douglas is often cited by papers focused on Genomics and Rare Diseases (23 papers), Cancer Genomics and Diagnostics (18 papers) and BRCA gene mutations in cancer (14 papers). Michael P. Douglas collaborates with scholars based in United States, Canada and Australia. Michael P. Douglas's co-authors include Kathryn A. Phillips, W. David Dotson, Glenn E. Palomaki, Patricia A. Deverka, Linda Bradley, Julia R. Trosman, James E. Haddow, Alfred O. Berg, Steven M. Teutsch and Ned Calonge and has published in prestigious journals such as JAMA, Nature Biotechnology and Journal of Clinical Microbiology.

In The Last Decade

Michael P. Douglas

59 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group

2009 484 citations Linda Bradley, Glenn E. Palomaki et al. Genetics in Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael P. Douglas United States	23	698	454	439	301	282	61	2.0k
Steven Hirschfeld United States	23	490 0.7×	802 1.8×	180 0.4×	145 0.5×	338 1.2×	72	2.1k
Sharon Hensley Alford United States	24	747 1.1×	189 0.4×	199 0.5×	92 0.3×	331 1.2×	53	1.5k
Chorh Chuan Tan Singapore	21	281 0.4×	428 0.9×	241 0.5×	264 0.9×	225 0.8×	43	3.3k
Susanne B. Haga United States	31	1.5k 2.1×	375 0.8×	181 0.4×	355 1.2×	165 0.6×	115	3.1k
Susanne Möller Denmark	29	317 0.5×	271 0.6×	860 2.0×	89 0.3×	1.4k 4.8×	82	2.8k
David Pee United States	27	538 0.8×	396 0.9×	372 0.8×	68 0.2×	1.1k 4.0×	48	3.5k
Paul Lacaze Australia	24	463 0.7×	591 1.3×	147 0.3×	87 0.3×	86 0.3×	103	1.8k
Brenda M. Birmann United States	25	150 0.2×	540 1.2×	397 0.9×	44 0.1×	465 1.6×	85	2.2k
Hutcha Sriplung Thailand	26	158 0.2×	454 1.0×	317 0.7×	72 0.2×	852 3.0×	172	2.7k
Melinda C. Aldrich United States	29	249 0.4×	679 1.5×	246 0.6×	72 0.2×	639 2.3×	103	2.8k

Countries citing papers authored by Michael P. Douglas

Since Specialization

Citations

This map shows the geographic impact of Michael P. Douglas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael P. Douglas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael P. Douglas more than expected).

Fields of papers citing papers by Michael P. Douglas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael P. Douglas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael P. Douglas. The network helps show where Michael P. Douglas may publish in the future.

Co-authorship network of co-authors of Michael P. Douglas

This figure shows the co-authorship network connecting the top 25 collaborators of Michael P. Douglas. A scholar is included among the top collaborators of Michael P. Douglas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael P. Douglas. Michael P. Douglas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wilson, Leslie, et al.. (2025). Outcomes and Preferences for Decision-Making for Upper Limb Prosthetic Care: The Patient Journey: A Scoping Literature Review. Archives of Rehabilitation Research and Clinical Translation. 7(2). 100460–100460.

Douglas, Michael P., et al.. (2025). The Missing Dose: Integrating Harm Reduction into Pharmacy Curriculums. PubMed. 47(1). 9–14.

Jansen, Jeroen P., Meera Vimala Ragavan, Cheng Chen, Michael P. Douglas, & Kathryn A. Phillips. (2023). The Health Inequality Impact of Liquid Biopsy to Inform First-Line Treatment of Advanced Non–Small Cell Lung Cancer: A Distributional Cost-Effectiveness Analysis. Value in Health. 26(12). 1697–1710. 6 indexed citations

Benge, Jared F., Andrew M. Kiselica, Alyssa Aguirre, et al.. (2022). Technology use and subjective cognitive concerns in older adults. Archives of Gerontology and Geriatrics. 106. 104877–104877. 14 indexed citations

Lin, Grace A., Julia R. Trosman, Michael P. Douglas, et al.. (2021). Influence of payer coverage and out‐of‐pocket costs on ordering of NGS panel tests for hereditary cancer in diverse settings. Journal of Genetic Counseling. 31(1). 130–139. 21 indexed citations

Scheuner, Maren T., et al.. (2021). Laboratory business models and practices: implications for availability and access to germline genetic testing. Genetics in Medicine. 23(9). 1681–1688. 4 indexed citations

Phillips, Kathryn A., Julia R. Trosman, Michael P. Douglas, et al.. (2021). US private payers’ perspectives on insurance coverage for genome sequencing versus exome sequencing: A study by the Clinical Sequencing Evidence-Generating Research Consortium (CSER). Genetics in Medicine. 24(1). 238–244. 8 indexed citations

Deverka, Patricia A., Michael P. Douglas, & Kathryn A. Phillips. (2020). Use of Real-World Evidence in US Payer Coverage Decision-Making for Next-Generation Sequencing–Based Tests: Challenges, Opportunities, and Potential Solutions. Value in Health. 23(5). 540–550. 23 indexed citations

Christensen, Kurt D., Jason L. Vassy, Kathryn A. Phillips, et al.. (2018). Short-term costs of integrating whole-genome sequencing into primary care and cardiology settings: a pilot randomized trial. Genetics in Medicine. 20(12). 1544–1553. 19 indexed citations

10.

Douglas, Michael P., et al.. (2018). Private payer coverage policies for exome sequencing (ES) in pediatric patients: trends over time and analysis of evidence cited. Genetics in Medicine. 21(1). 152–160. 27 indexed citations

11.

Phillips, Kathryn A., Patricia A. Deverka, Harold C. Sox, et al.. (2017). Making genomic medicine evidence-based and patient-centered: a structured review and landscape analysis of comparative effectiveness research. Genetics in Medicine. 19(10). 1–11. 42 indexed citations

12.

Trosman, Julia R., Christine B. Weldon, Michael P. Douglas, et al.. (2017). Decision Making on Medical Innovations in a Changing Health Care Environment: Insights from Accountable Care Organizations and Payers on Personalized Medicine and Other Technologies. Value in Health. 20(1). 40–46. 15 indexed citations

13.

Chambers, James D., et al.. (2017). EXAMINING EVIDENCE IN U.S. PAYER COVERAGE POLICIES FOR MULTI-GENE PANELS AND SEQUENCING TESTS. International Journal of Technology Assessment in Health Care. 33(4). 534–540. 21 indexed citations

14.

Trosman, Julia R., et al.. (2015). Availability and payer coverage of BRCA1/2 tests and gene panels. Nature Biotechnology. 33(9). 900–902. 19 indexed citations

15.

Clyne, Mindy, Sheri D. Schully, W. David Dotson, et al.. (2014). Horizon scanning for translational genomic research beyond bench to bedside. Genetics in Medicine. 16(7). 535–538. 22 indexed citations

16.

Phillips, Kathryn A., Julie Sakowski, Julia R. Trosman, et al.. (2013). The economic value of personalized medicine tests: what we know and what we need to know. Genetics in Medicine. 16(3). 251–257. 76 indexed citations

17.

Dotson, W. David, Michael P. Douglas, Katherine Kolor, et al.. (2013). Prioritizing Genomic Applications for Action by Level of Evidence: A Horizon-Scanning Method. Clinical Pharmacology & Therapeutics. 95(4). 394–402. 46 indexed citations

18.

Palomaki, Glenn E., et al.. (2013). Use of genomic panels to determine risk of developing type 2 diabetes in the general population: a targeted evidence-based review. Genetics in Medicine. 15(8). 600–611. 7 indexed citations

19.

Palomaki, Glenn E., Linda Bradley, Michael P. Douglas, Katherine Kolor, & W. David Dotson. (2009). Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review. Genetics in Medicine. 11(1). 21–34. 99 indexed citations

20.

Douglas, Michael P. & Scott O. Rogers. (1998). DNA damage caused by common cytological fixatives. Mutation research. Fundamental and molecular mechanisms of mutagenesis. 401(1-2). 77–88. 89 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact